Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs
Sapience Therapeutics has raised $2.0M in total funding. The most recent round was Grant. The last funding was announced in May 2023.
Sapience Therapeutics's investors include Bristol-Myers Squibb, Connectivity Ventures Fund, Kingdon Capital, National Institute of Allergy and Infectious Diseases, Celgene.
Sapience Therapeutics is headquartered in Scarsdale, United States.
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs
Sapience Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sapience Therapeutics — Funding & Investors." VCBacked, May 4, 2023, https://www.vcbacked.co/company/sapience-therapeutics. Accessed August 14, 2026.
VCBacked. (2023). Sapience Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/sapience-therapeutics
{{cite web |title=Sapience Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sapience-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated